Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | UCARTCS1A |
Synonyms | |
Therapy Description |
UCARTCS1A is a preparation of allogeneic T-lymphocytes engineered with TALEN to express a chimeric antigen receptor (CAR) that targets CS1 (SLAMF7), which potentially induces cytotoxicity and may result in lysis of tumor cells expressing CS1 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
UCARTCS1A | UCART CS1A|UCART-CS1A|Allogeneic TALEN Gene-edited UCARTCS1A | UCARTCS1A is a preparation of allogeneic T-lymphocytes engineered with TALEN to express a chimeric antigen receptor (CAR) that targets CS1 (SLAMF7), which potentially induces cytotoxicity and may result in lysis of tumor cells expressing CS1 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04142619 | Phase I | UCARTCS1A | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) | Terminated | USA | 0 |